FAP and neoplasm: Based on data showing immune control of tumor growth and effectiveness of immune checkpoint inhibitors after FAP inhibition in a KPC mouse model [37], FAP inhibition is currently being explored in association with pembrolizumab (anti-PD1) (NCT04171219, NCT03910660, NCT04007744).